Latest Innovation News

Image Resources NL reported a strong finish to 2025 with record heavy mineral concentrate production and sales, alongside promising developments in its gold exploration and synthetic rutile innovation.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

MEC Resources has bolstered its stake in Advent Energy with a $1.55 million loan while navigating a pivotal Federal Court hearing on the PEP 11 Joint Venture. Meanwhile, progress on Clean Hydrogen Technology signals potential growth avenues.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Ionic Rare Earths has advanced its global rare earths strategy with a key US partnership, significant UK government funding, and progress in Brazil and Uganda, positioning itself as a critical player in sustainable magnet recycling and heavy rare earth supply.

Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.

Renascor Resources is advancing its government-backed Purified Spherical Graphite demonstration facility in Adelaide, poised to challenge China’s dominance in battery anode materials with an innovative HF-free process.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.